Answers are grounded in this paper and cite their sources.
Explores gene expression links to chondrosarcoma, suggesting potential therapeutic targets.
To systematically explore causal relationships between chondrosarcoma and angiogenesis-related gene expression using Mendelian randomization (MR) and transcriptome-wide association study (TWAS) approaches, and identify potential therapeutic targets. Based on whole blood tissue gene expression data, summary-data-based Mendelian randomization (SMR) analysis was performed to examine causal associations between 25 angiogenesis-related candidate genes and chondrosarcoma risk. Simultaneously, transcriptome-wide association study (TWAS) was conducted covering 22 autosomes, calculating Z-scores and P-values to assess the strength of association between gene expression and disease. Key findings were validated by RT-qPCR in chondrosarcoma cell lines versus normal chondrocytes. SMR analysis identified significant causal associations after correction. LINC00984 showed the strongest risk association (OR = 5.243, P = 1.10 × 10-2), while TXNDC2 also demonstrated risk effects (OR = 3.555, P = 5.09 × 10-3). Protective genes included MPL28 (OR = 0.070, P = 1.40 × 10-2) and RP11-474N24.6 (OR = 0.287, P = 1.92 × 10-3). TWAS identified significant signals on chromosomes 18–19 and 22. Functional analysis confirmed enrichment in VEGF and HIF-1 pathways. RT-qPCR validation showed risk genes were upregulated 3.2–8.2-fold in tumor cells, while protective genes were downregulated 58–78% (all P < 0.01). This study identified multiple angiogenesis-regulatory genes significantly associated with chondrosarcoma through large-scale genetic analysis, revealing complex molecular mechanisms of disease development and providing important genetic evidence for precision therapeutic strategy development.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: